ALT5 Sigma Corporation $AIFC is Crcm LP’s 6th Largest Position

Crcm LP lifted its position in shares of ALT5 Sigma Corporation (NASDAQ:AIFC) by 373.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 10,941,280 shares of the company’s stock after purchasing an additional 8,629,103 shares during the quarter. ALT5 Sigma comprises approximately 4.1% of Crcm LP’s holdings, making the stock its 6th largest holding. Crcm LP owned approximately 8.66% of ALT5 Sigma worth $12,035,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Profund Advisors LLC purchased a new stake in shares of ALT5 Sigma during the 3rd quarter worth about $28,000. Arete Wealth Advisors LLC purchased a new stake in shares of ALT5 Sigma during the 3rd quarter worth about $28,000. Victory Capital Management Inc. acquired a new position in ALT5 Sigma during the 3rd quarter worth approximately $33,000. Lantern Wealth Advisors LLC acquired a new position in ALT5 Sigma during the 3rd quarter worth approximately $36,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in ALT5 Sigma during the 3rd quarter worth approximately $45,000. Hedge funds and other institutional investors own 6.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered ALT5 Sigma from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

ALT5 Sigma Stock Up 0.5%

ALT5 Sigma stock opened at $0.66 on Friday. The stock’s 50 day moving average price is $0.89 and its 200 day moving average price is $1.33. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.82 and a quick ratio of 0.82. ALT5 Sigma Corporation has a one year low of $0.63 and a one year high of $10.80.

ALT5 Sigma (NASDAQ:AIFC) last announced its earnings results on Monday, May 18th. The company reported ($2.14) earnings per share (EPS) for the quarter. ALT5 Sigma had a negative net margin of 2,483.94% and a negative return on equity of 68.25%. The business had revenue of $4.71 million during the quarter.

ALT5 Sigma Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.